Mission Bay Capital

Mission Bay Capital is a venture capital firm based in San Francisco, focused on early-stage investments in the biosciences. Established in 2009, the firm aims to support innovative entrepreneurs addressing critical medical and environmental challenges. Their portfolio includes companies like Caribou Biosciences, Alector, Zymergen, and Mammoth Biosciences, which utilize cutting-edge technologies such as CRISPR for molecular diagnostics​​. The firm has recently raised its third fund, totaling $60 million, which will continue to invest broadly in biotechnology innovations. Mission Bay Capital operates MBC BioLabs, a life-science incubator that has helped launch 138 companies, raising over $3.5 billion in total. This incubator provides state-of-the-art equipment and services to early-stage biotech companies, enabling them to advance their research and development efficiently​. Mission Bay Capital is led by Douglas Crawford, Ph.D., along with a team of experienced professionals like Robert Blazej, Ph.D. They emphasize disciplined investing and a management culture rooted in respect and inclusion, aiming to deliver superior returns and strategic opportunities to their limited partners​.